Bristol Myers’ Bowel Disease Drug Fails in Late-stage Study

Bristol Myers Squibb’s experimental drug for Crohn’s disease, ozanimod, did not help patients achieve disease remission in a late-stage study. Crohn’s is a chronic bowel disease causing inflammation in the digestive tract, leading to symptoms like diarrhea, abdominal pain, and fatigue. The drug, acquired through a buyout of Celgene, did not result in a significant improvement in gastrointestinal symptoms after 12 weeks compared to a placebo. Ozanimod, approved as Zeposia for other conditions, generated sales of $434 million in 2023. Bristol Myers will analyze trial data and share results with the scientific community after AbbVie’s Rinvoq was approved for Crohn’s disease last year.

Source link

error: Content is protected !!